Sheree H. Waslaske

12-P: Improved detection of HLA antibodies by LABScreen® single antigen using a Biotin-Streptavidin complex system

P015 Removal of selected non-specific reactivity in single antigen bead assays via FBS pre-treatment

OR14 HLA class I antibodies increased WNT/β-catenin pathway component protein lymphoid-binding factor 1 (LEF1) in endothelial cells in foxo1 protein dependent fashion

P031 : NO MORE POOLED POSITIVE CONTROL SERUM: POSITIVE CONTROL SERUM FOR THE STANDARDIZATION OF HLA LABORATORY ASSAYS USING A COMBINATION OF CHIMERIC MONOCLONAL ANTIBODIES AGAINST HLA AND AB NEGATIVE SERUM

35-P : POSTIVE FLOW CYTOMETRY CROSMMATCH DUE TO LOW LEVELS OF NON-SELF PAN A LOCUS ANTIBODY: CHARACTERIZED BY BIOLOGICAL AND BIOINFORMATICAL APPROACHES

37-P: FORMATION OF HLA ANTIBODIES IN NON-SENSITIZED PATIENTS AFTER IMMEDIATE GRAFT LOSS FOR NON-IMMUNOLOGICAL CAUSES

52-P: CARDIAC TRANSPLANTATION OF HIGHLY SENSITIZED PATIENTS ACROSS C1Q NEGATIVE HLA ANTIBODIES

46-P: Evaluation of the whole genome amplification procedure in routine HLA typing of stem cells transplantation candidates

45-P: Use of the Luminex HDID beads for rapid evaluation of the quality of pooled positive control serum for the use in flow cytometric crossmatch and antibodies screening assays

3-P: Current UNET algorithm is inadequate for allocating organs to sensitized patients